Introducing

Our Portfolio

“It is always easy to talk about a good partner. From Beta Capital you can expect honesty and firmness in opinions, but always with the necessary flexibility to know how to listen and work as a team, in order to arrive at better decisions. I don’t forget that they were always by our side, especially in some difficult moments.”

Pedro Fernandes, Founder and CEO Bullet Solutions

“We are grateful for the support that Beta Capital has given us particularly during the early years. The investment rounds supported the company until the MBO led by Nonius founders. I leave the challenge to Beta Capital to contribute to more similar cases.“

António Silva, Founder and CEO Nonius

“Beta Capital was essential in the creation process of Biopremier for believing and investing in the original project. Throughout its growth, BIopremier has always counted on Beta Capital’s support, experience and active role in defining growth and innovation strategies, culminating in a successful project with international recognition in the agri-food area.”

Mário Gadanho, Founder Biopremier

“Beta Capital has been a partner of Stemmatters
since its beginning. Beta Capital understood well the dynamic nature of our activity, providing fundamental support for the realization of our business potential, and contributing to the stability and overcoming of the many challenges faced.“

Rui A. Sousa, Founder and CEO Stemmatters

“When the road is tough, one must choose its venture partners well! Beta Capital has been the perfect partner towards success. The support went far beyond the funding, being Beta Capital always present during difficult times and situations, backing us. And together we have celebrated success!“
João Paulo Breia, Founder Ambilab

“It is always easy to talk about a good partner. From Beta Capital you can expect honesty and firmness in opinions, but always with the necessary flexibility to know how to listen and work as a team, in order to arrive at better decisions. I don’t forget that they were always by our side, especially in some difficult moments.

Pedro Fernandes, Founder and CEO Bullet Solutions

“We are grateful for the support that Beta Capital has given us particularly during the early years. The investment rounds supported the company until the MBO led by Nonius founders. I leave the challenge to Beta Capital to contribute to more similar cases.“

António Silva, Founder and CEO Nonius

“Beta Capital was essential in the creation process of Biopremier for believing and investing in the original project. Throughout its growth, BIopremier has always counted on Beta Capital’s support, experience and active role in defining growth and innovation strategies, culminating in a successful project with international recognition in the agri-food area.”
Mário Gadanho, Founder Biopremier
“Beta Capital has been a partner of Stemmatters since its beginning. Beta Capital understood well the dynamic nature of our activity, providing fundamental support for the realization of our business potential, and contributing to the stability and overcoming of the many challenges faced. “
Rui A. Sousa, Founder and CEO Stemmatters
“When the road is tough, one must choose its venture partners well! Beta Capital has been the perfect partner towards success. The support went far beyond the funding, being Beta Capital always present during difficult times and situations, backing us. And together we have celebrated success! “
João Paulo Breia, Founder Ambilab

PORTFOLIO NEWS

Alfama

Entry Year: 2006 

Exit Year: 2018

Pharmaceutical company dedicated to the development of small-molecule drugs for unmet medical needs.

Ambilab

Entry Year: 2006

Exit Year: 2013

Global services company performing testing and technical analysis in the environmental area.

Aquacria

Entry Year: 2006 

Exit Year: 2012

Aquaculture company of an intensive turbot system and sole, as well as the respective commercialization.

Biocant Ventures

Entry Year: 2006

Exit Year: 2019

Venture capital firm seeking to invest in seed and early-stage companies operating in the in the life sciences, oncology, healthcare and pharmaceuticals sectors.

Bioinnovation

Biotechnology company dedicated to the development and commercialization of biotech platforms, with expertise in biocatalysis.

Biopremier

Entry Year: 2006

Exit Year: 2016

Diagnostic company based on real time PCR kits created to serve the agri-food, clinical and veterinary sectors.

Biosurfit

Entry Year: 2006 

 

First and only diagnostic company diagnostics system capable of performing the major PoC blood test modalities (hematology, immunoassays and clinical chemistry) on the same instrument. Developer of the spinit technology, a fully automated diagnostics solution with just one drop of blood.

Bullet Solutions

Entry Year: 2014

SaaS company developer of scheduling and timetabling software designed to automatically solve complex processes and decisions.

Clamitech

Entry Year: 2008

Exit Year: 2015

Biotechnology company dedicated to R&D, production and commercialization of fungi based biopesticides.

Crivo Ventures

Entry Year: 2006

Exit Year: 2019

Venture capital firm supporting university spin-offs, researchers or business projects, in the areas of physical sciences and engineering.

Equigerminal

Entry Year: 2012 

Exit Year: 2016

Biotechnology company dedicated to the diagnosis and therapy of the New Equine Virus (NEV) in horses.

FWD (Boavista Windows)

Entry Year: 2020

FWD is the developer of the first European brand of window systems fully manufactured in fibreglass – Boavista Windows

Genepredit

Entry Year: 2007

Exit Year: 2020

Biotechnology company dedicated to the development of a new targeted treatment for obesity.

Growth Oriented Development

Entry Year: 2006

Exit Year: 2010

Software company developing modeling tools to accelerate the software development process.

Heartgenetics

Entry Year: 2015

Exit Year: 2020

Digital health and genetic testing company using machine learning methods and data analytics to provide actionable and cost-effective genetic tests with highly scalable applications in well-being, cardiovascular genetics and pharmacogenetics

Idea Puzzle

Entry Year: 2008

Software company developer of a decision-making tool designed to assist Ph.D. students coherently align the theory, method, data, rhetoric and authorship of a research proposal.

Interactome

Entry Year: 2009

Exit Year: 2015

Biotechnology company dedicated to the identification of new protein complexes through a mathematical algorithm.

Magnomics

Entry Year: 2014

Exit Year: 2020

Biotechnology company dedicated to the development the next generation of fully portable, easy to use in-vitro molecular diagnostic devices, in particular the detection of bovine mastitis causing pathogens in milk.

Matera

Entry Year: 2011

Exit Year: 2020

Biotechnology company dedicated to the development of bio-nanotechnology designed to offer development services of materials and surfaces with antimicrobial properties.

Nonius

Entry Year: 2006

Exit Year: 2015

IT company dedicated to the development and commercialization of digital guest services for the global hospitality sector as well as hospitals and cruise ships, being a top 10 player worldwide with over 320.000 rooms using its technology.

Pronto e Fresco

Entry Year: 2006

Exit Year: 2010

Industrial company dedicated to the the transformation and commercialization of fish in innovative formats.

Quattro energy

Entry Year: 2009

Exit Year: 2011

Industrial company dedicated to the development, production and commercialization of heat pumps and other solutions for increasing energy efficiency

Spinvalor

Entry Year: 2006

Exit Year: 2011

Venture capital firm supporting university spin-offs, researchers or business projects.

Stemmaters

Entry Year: 2011

Biotechnology company provinding CDMO services in cell therapies, tissue products and blood-derived biologicals, complemented with a hydrogel formulation platform. Stemmatters’ STM-148B has been specifically designed as a proprietary, fully chemically defined, biodegradable matrix for cartilage repair applications.

Thelial

Entry Year: 2007

Exit Year: 2016

Pharmaceutical company dedicated to targeted drug discovery platform, with drug candidates in two orphan diseases characterised by tight junction defect.